Global Pancreatic Endocrine Tumor Drug Market Insights and Forecast to 2028

Publisher Name :
Date: 17-Feb-2022
No. of pages: 90
Inquire Before Buying

Pancreatic Endocrine Tumor Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Pancreatic Endocrine Tumor Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

- Buparlisib Hydrochloride

- Dovitinib Lactate

- Fosbretabulin Tromethamine

- Lanreotide Acetate

- MPHE-001B

- Others

Segment by Application

- Clinic

- Research Center

- Hospital

By Company

- Ipsen S.A.

- Jiangsu Hengrui Medicine Co., Ltd.

- MediaPharma s.r.l.

- Novartis AG

- OXiGENE, Inc.

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

Global Pancreatic Endocrine Tumor Drug Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Pancreatic Endocrine Tumor Drug Product Introduction
1.2 Market by Type
1.2.1 Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Buparlisib Hydrochloride
1.2.3 Dovitinib Lactate
1.2.4 Fosbretabulin Tromethamine
1.2.5 Lanreotide Acetate
1.2.6 MPHE-001B
1.2.7 Others
1.3 Market by Application
1.3.1 Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Research Center
1.3.4 Hospital
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Pancreatic Endocrine Tumor Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Pancreatic Endocrine Tumor Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Pancreatic Endocrine Tumor Drug Sales by Region
2.4.1 Global Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022)
2.4.2 Global Sales Pancreatic Endocrine Tumor Drug by Region (2023-2028)
2.5 Global Pancreatic Endocrine Tumor Drug Revenue by Region
2.5.1 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022)
2.5.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Pancreatic Endocrine Tumor Drug Sales by Manufacturers
3.1.1 Global Top Pancreatic Endocrine Tumor Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Pancreatic Endocrine Tumor Drug in 2021
3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers
3.2.1 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Pancreatic Endocrine Tumor Drug Revenue in 2021
3.3 Global Pancreatic Endocrine Tumor Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Pancreatic Endocrine Tumor Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Pancreatic Endocrine Tumor Drug Sales by Type
4.1.1 Global Pancreatic Endocrine Tumor Drug Historical Sales by Type (2017-2022)
4.1.2 Global Pancreatic Endocrine Tumor Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
4.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type
4.2.1 Global Pancreatic Endocrine Tumor Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Pancreatic Endocrine Tumor Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
4.3 Global Pancreatic Endocrine Tumor Drug Price by Type
4.3.1 Global Pancreatic Endocrine Tumor Drug Price by Type (2017-2022)
4.3.2 Global Pancreatic Endocrine Tumor Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Pancreatic Endocrine Tumor Drug Sales by Application
5.1.1 Global Pancreatic Endocrine Tumor Drug Historical Sales by Application (2017-2022)
5.1.2 Global Pancreatic Endocrine Tumor Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
5.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application
5.2.1 Global Pancreatic Endocrine Tumor Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Pancreatic Endocrine Tumor Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
5.3 Global Pancreatic Endocrine Tumor Drug Price by Application
5.3.1 Global Pancreatic Endocrine Tumor Drug Price by Application (2017-2022)
5.3.2 Global Pancreatic Endocrine Tumor Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Pancreatic Endocrine Tumor Drug Market Size by Type
6.1.1 North America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
6.1.2 North America Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
6.2 North America Pancreatic Endocrine Tumor Drug Market Size by Application
6.2.1 North America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
6.2.2 North America Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
6.3 North America Pancreatic Endocrine Tumor Drug Market Size by Country
6.3.1 North America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2028)
6.3.2 North America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Pancreatic Endocrine Tumor Drug Market Size by Type
7.1.1 Europe Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
7.1.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
7.2 Europe Pancreatic Endocrine Tumor Drug Market Size by Application
7.2.1 Europe Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
7.2.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
7.3 Europe Pancreatic Endocrine Tumor Drug Market Size by Country
7.3.1 Europe Pancreatic Endocrine Tumor Drug Sales by Country (2017-2028)
7.3.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size by Type
8.1.1 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size by Application
8.2.1 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size by Region
8.3.1 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Pancreatic Endocrine Tumor Drug Market Size by Type
9.1.1 Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
9.1.2 Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
9.2 Latin America Pancreatic Endocrine Tumor Drug Market Size by Application
9.2.1 Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
9.2.2 Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
9.3 Latin America Pancreatic Endocrine Tumor Drug Market Size by Country
9.3.1 Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2028)
9.3.2 Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Type
10.1.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Application
10.2.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Country
10.3.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Ipsen S.A.
11.1.1 Ipsen S.A. Corporation Information
11.1.2 Ipsen S.A. Overview
11.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Ipsen S.A. Recent Developments
11.2 Jiangsu Hengrui Medicine Co., Ltd.
11.2.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
11.2.2 Jiangsu Hengrui Medicine Co., Ltd. Overview
11.2.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
11.3 MediaPharma s.r.l.
11.3.1 MediaPharma s.r.l. Corporation Information
11.3.2 MediaPharma s.r.l. Overview
11.3.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 MediaPharma s.r.l. Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Corporation Information
11.4.2 Novartis AG Overview
11.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis AG Recent Developments
11.5 OXiGENE, Inc.
11.5.1 OXiGENE, Inc. Corporation Information
11.5.2 OXiGENE, Inc. Overview
11.5.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 OXiGENE, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Pancreatic Endocrine Tumor Drug Industry Chain Analysis
12.2 Pancreatic Endocrine Tumor Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pancreatic Endocrine Tumor Drug Production Mode & Process
12.4 Pancreatic Endocrine Tumor Drug Sales and Marketing
12.4.1 Pancreatic Endocrine Tumor Drug Sales Channels
12.4.2 Pancreatic Endocrine Tumor Drug Distributors
12.5 Pancreatic Endocrine Tumor Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Pancreatic Endocrine Tumor Drug Industry Trends
13.2 Pancreatic Endocrine Tumor Drug Market Drivers
13.3 Pancreatic Endocrine Tumor Drug Market Challenges
13.4 Pancreatic Endocrine Tumor Drug Market Restraints
14 Key Findings in The Global Pancreatic Endocrine Tumor Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Buparlisib Hydrochloride
Table 3. Major Manufacturers of Dovitinib Lactate
Table 4. Major Manufacturers of Fosbretabulin Tromethamine
Table 5. Major Manufacturers of Lanreotide Acetate
Table 6. Major Manufacturers of MPHE-001B
Table 7. Major Manufacturers of Others
Table 8. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 10. Global Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)
Table 11. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2017-2022)
Table 12. Global Pancreatic Endocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)
Table 13. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2023-2028)
Table 14. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022) & (US$ Million)
Table 15. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2017-2022)
Table 16. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028) & (US$ Million)
Table 17. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2023-2028)
Table 18. Global Pancreatic Endocrine Tumor Drug Sales by Manufacturers (2017-2022) & (K Pcs)
Table 19. Global Pancreatic Endocrine Tumor Drug Sales Share by Manufacturers (2017-2022)
Table 20. Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 21. Global Pancreatic Endocrine Tumor Drug Revenue Share by Manufacturers (2017-2022)
Table 22. Pancreatic Endocrine Tumor Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 23. Global Pancreatic Endocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Pancreatic Endocrine Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pancreatic Endocrine Tumor Drug as of 2021)
Table 25. Pancreatic Endocrine Tumor Drug Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Pancreatic Endocrine Tumor Drug Product Offered
Table 27. Date of Manufacturers Enter into Pancreatic Endocrine Tumor Drug Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 30. Global Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 31. Global Pancreatic Endocrine Tumor Drug Sales Share by Type (2017-2022)
Table 32. Global Pancreatic Endocrine Tumor Drug Sales Share by Type (2023-2028)
Table 33. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 34. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 35. Global Pancreatic Endocrine Tumor Drug Revenue Share by Type (2017-2022)
Table 36. Global Pancreatic Endocrine Tumor Drug Revenue Share by Type (2023-2028)
Table 37. Pancreatic Endocrine Tumor Drug Price by Type (2017-2022) & (USD/Pcs)
Table 38. Global Pancreatic Endocrine Tumor Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 39. Global Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 40. Global Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 41. Global Pancreatic Endocrine Tumor Drug Sales Share by Application (2017-2022)
Table 42. Global Pancreatic Endocrine Tumor Drug Sales Share by Application (2023-2028)
Table 43. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 44. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 45. Global Pancreatic Endocrine Tumor Drug Revenue Share by Application (2017-2022)
Table 46. Global Pancreatic Endocrine Tumor Drug Revenue Share by Application (2023-2028)
Table 47. Pancreatic Endocrine Tumor Drug Price by Application (2017-2022) & (USD/Pcs)
Table 48. Global Pancreatic Endocrine Tumor Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 49. North America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 50. North America Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 51. North America Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 52. North America Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 53. North America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 54. North America Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 55. North America Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 56. North America Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 57. North America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 58. North America Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 59. North America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (US$ Million)
Table 60. North America Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (US$ Million)
Table 61. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 62. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 63. Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 64. Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 65. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 66. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 67. Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 68. Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 69. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 70. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 71. Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (US$ Million)
Table 72. Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (US$ Million)
Table 73. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 74. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 75. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 76. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 77. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 78. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 79. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 80. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 81. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)
Table 82. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)
Table 83. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022) & (US$ Million)
Table 84. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028) & (US$ Million)
Table 85. Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 86. Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 87. Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 88. Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 89. Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 90. Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 91. Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 92. Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 93. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 94. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 95. Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (US$ Million)
Table 96. Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 98. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 99. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 102. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 103. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 105. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 106. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 107. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (US$ Million)
Table 108. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (US$ Million)
Table 109. Ipsen S.A. Corporation Information
Table 110. Ipsen S.A. Description and Major Businesses
Table 111. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 112. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Ipsen S.A. Recent Developments
Table 114. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
Table 115. Jiangsu Hengrui Medicine Co., Ltd. Description and Major Businesses
Table 116. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 117. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
Table 119. MediaPharma s.r.l. Corporation Information
Table 120. MediaPharma s.r.l. Description and Major Businesses
Table 121. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 122. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. MediaPharma s.r.l. Recent Developments
Table 124. Novartis AG Corporation Information
Table 125. Novartis AG Description and Major Businesses
Table 126. Novartis AG Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 127. Novartis AG Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Novartis AG Recent Developments
Table 129. OXiGENE, Inc. Corporation Information
Table 130. OXiGENE, Inc. Description and Major Businesses
Table 131. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 132. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. OXiGENE, Inc. Recent Developments
Table 134. Key Raw Materials Lists
Table 135. Raw Materials Key Suppliers Lists
Table 136. Pancreatic Endocrine Tumor Drug Distributors List
Table 137. Pancreatic Endocrine Tumor Drug Customers List
Table 138. Pancreatic Endocrine Tumor Drug Market Trends
Table 139. Pancreatic Endocrine Tumor Drug Market Drivers
Table 140. Pancreatic Endocrine Tumor Drug Market Challenges
Table 141. Pancreatic Endocrine Tumor Drug Market Restraints
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Pancreatic Endocrine Tumor Drug Product Picture
Figure 3. Global Pancreatic Endocrine Tumor Drug Market Share by Type in 2021 & 2028
Figure 3. Buparlisib Hydrochloride Product Picture
Figure 4. Dovitinib Lactate Product Picture
Figure 5. Fosbretabulin Tromethamine Product Picture
Figure 6. Lanreotide Acetate Product Picture
Figure 7. MPHE-001B Product Picture
Figure 8. Others Product Picture
Figure 9. Global Pancreatic Endocrine Tumor Drug Market Share by Application in 2021 & 2028
Figure 10. Clinic
Figure 11. Research Center
Figure 12. Hospital
Figure 13. Pancreatic Endocrine Tumor Drug Report Years Considered
Figure 14. Global Pancreatic Endocrine Tumor Drug Sales 2017-2028 (K Pcs)
Figure 15. Global Pancreatic Endocrine Tumor Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Pancreatic Endocrine Tumor Drug Revenue 2017-2028 (US$ Million)
Figure 17. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 18. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2017-2022)
Figure 19. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2023-2028)
Figure 20. North America Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 21. North America Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Europe Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 23. Europe Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 25. Asia-Pacific Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Latin America Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 27. Latin America Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 29. Middle East & Africa Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 30. The Pancreatic Endocrine Tumor Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 31. The Top 5 and 10 Largest Manufacturers of Pancreatic Endocrine Tumor Drug in the World: Market Share by Pancreatic Endocrine Tumor Drug Revenue in 2021
Figure 32. Global Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 33. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 34. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 35. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 36. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 37. North America Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 38. North America Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 39. North America Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 40. North America Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 41. North America Pancreatic Endocrine Tumor Drug Sales Share by Country (2017-2028)
Figure 42. North America Pancreatic Endocrine Tumor Drug Revenue Share by Country (2017-2028)
Figure 43. U.S. Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 44. Canada Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 45. Europe Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 46. Europe Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 47. Europe Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 48. Europe Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 49. Europe Pancreatic Endocrine Tumor Drug Sales Share by Country (2017-2028)
Figure 50. Europe Pancreatic Endocrine Tumor Drug Revenue Share by Country (2017-2028)
Figure 51. Germany Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 52. France Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 53. U.K. Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 54. Italy Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 55. Russia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 56. Asia Pacific Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 57. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 58. Asia Pacific Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 59. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 60. Asia Pacific Pancreatic Endocrine Tumor Drug Sales Share by Region (2017-2028)
Figure 61. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue Share by Region (2017-2028)
Figure 62. China Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 63. Japan Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 64. South Korea Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 65. India Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 66. Australia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 67. Taiwan Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Indonesia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 69. Thailand Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 70. Malaysia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 71. Philippines Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 72. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share by Type
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs